Role of gasdermin family proteins in the occurrence and progression of hepatocellular carcinoma

Yandong Miao a,*,1, Yonggang Chen b,1, Denghai Mi c

a The Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The 2nd Medical College of Binzhou Medical University, Yantai 264000, Shandong Province, China
b Shenzhen Hospital of Southern Medical University, Shenzhen 518100, Guangdong Province, China
c Gansu Academy of Traditional Chinese Medicine, Lanzhou 730000, Gansu Province, China

ARTICLE INFO

Keywords:
Hepatocellular carcinoma
Pyroptosis
Gasdermin
Liver cancer

ABSTRACT

Primary liver cancer is the sixth most common cancer and the third leading cause of cancer mortality worldwide, hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 75%–85% of cases. The occurrence and progression of HCC involve multiple events. Pyroptosis is a gasdermins mediated programmed cell death and is intricately associated with cancerogenesis, including HCC. This review mainly concerns the recent research advances of the gasdermin family members in HCC. The biological roles and specific expression patterns of the family members are discussed, especially those that are involved in the regulatory pathways in the occurrence and progression of HCC. We provide the latest progress into the distinct molecular mechanisms of gasdermin family members involved in the occurrence and development of HCC.

1. Introduction

More than 30 years have passed since Saeki et al. [1] first identified Gasdermin (GSDM), a recombinant inducible mutation 3 (Rim3), as a candidate gene associated with mouse skin mutant phenotype. Sato et al. found that Rim3 reveals over-proliferation and differentiation of epidermis and hair follicles in mice [2]. Comprehensive expression analysis demonstrated that GSDM family genes are exclusively expressed in the gastrointestinal and skin epithelium in a highly tissue-specific manner [1, 3, 4]. In 2007, Tamura et al. referred to the previously reported GSDM-associated genes [3, 4, 5] and the three new GSDM genes they identified as the GSDM family [6]. To date, six genes have been categorized as GSDM family members (GSDMs) based on their N-terminal and distinct regions conserved in humans (Table 1), including Gasdermin A (GSDMA) [1, 3], Gasdermin B (GSDMB) [5], Gasdermin C (GSDMC) [7], Gasdermin D (GSDMD), Gasdermin E (GSDME) [8, 9], and PJVK [10]. Previous studies have demonstrated that GSDMs are involved in regulating gastric epithelial cell progress and apoptosis [11, 12], pyroptosis [13, 14, 15], gasdermin-like (GSDML) might be a secretory or metabolic product involved in the secretory pathway [16], perform cell death and inflammation [17], the regulation of cancer occurrence and development [18, 19], cancer biology and antitumor immunity [20, 21], NETosis [22, 23], immune defenses and diseases [24, 25, 26]. Each member of the GSDM family has a different tissue specificity and plays a unique role in physiological or pathological processes [11, 24, 27]. Except for PJVK, the N-terminal structural domains released by GSDMA-E exhibit pore-forming activity on cell membranes and are effectors of pyroptosis [13, 26, 28, 29, 30] (Figure 1).

In 2020, primary liver cancer is the sixth most common cancer and the third leading cause of cancer mortality worldwide, approximately 906,000 new cases and 830,000 deaths [34]. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 75%–85% of cases [34, 35]. It is well known that hepatitis virus infection (including hepatitis B and hepatitis C virus) is the most significant risk factor for the development of HCC [36]. Other risk factors include aflatoxin-contaminated foods, heavy alcohol intake, et al. [34]. Non-alcoholic steatohepatitis (NASH), related to metabolic syndrome or diabetes, is becoming the fastest increasing cause of hepatocellular carcinoma, especially in the West country [37]. In addition, reports on mutational characteristics have confirmed aristolochic acid and tobacco as potential causative cofactors of HCC [38]. As research progresses, the role of the GSDM family in tumors is becoming more prominent [20, 39]. Several studies have demonstrated that specific drugs or molecules may trigger GSDMD-mediated pyroptosis in diverse types of cancer,
sugesting that this novel programed cell death is involved in cancer pathogenesis and may be a new target for cancer therapy, such as esophageal adenocarcinoma, gastric cancer, colorectal cancer (CRC), suggesting that this novel programmed cell death is involved in cancer pathogenesis and may be a new target for cancer therapy, such as esophageal adenocarcinoma, gastric cancer, colorectal cancer (CRC), etc. as we all know, pyroptosis is a gasdermin mediated programmed cell death [14]. Do GSDM family members also play an essential role in the progress of HCC? This review will summarize and discuss the potential impact of GSDM family members on HCC and their role in anticancer therapy. Moreover, we also supplemented the study by obtaining HCC data from The Cancer Genome Atlas (TCGA) database for bioinformatics analysis.

2. GSDMA

The GSDM gene is located on human chromosome 17q21.2 [6] (Figure 2A). Humans have only one copy of the gene encoding GSDMA, while mice have three isomers (GSDMA1-3). GSDMA is predominantly expressed in epithelial cells of the skin, differentiated upper gastrointestinal, and lung but is frequently suppressed in primary gastric cancer and gastric cancer cell lines [11, 41]. Moussette et al. have reported that GSDMA expression is up-regulated in the 5-aza-dC, a DNA methyltransferase inhibitor, treatment adenocarcinoma cell line MCF-7 [42]. Saeki et al. found that GSDMA expression is up-regulated through the transforming growth factor-β (TGF-β) and LIM structural domain 1 (LMO1) pathways, thereby promoting apoptosis in gastric epithelial cells [12]. Lin et al. found that Gasdermin A3 N-terminal functional domain modulates mitochondrial homeostasis through mitochondrial targeting [43].

Hu et al. reported that mRNA expression levels of GSDMA were higher in HCC tissues than in normal tissues by UALCAN databases [44]. We also discovered mRNA expression of GSDMA was accordantly higher in HCC tumors (377 TCGA-LIHC) compared with normal tissues (50 TCGA-LIHC paracancerous tissue and 110 GTEX-normal liver tissues) (Figure 2B). Further analysis of the GSDMA revealed the general existence of copy number variation (CNV) mutations. The genetic alteration rate of GSDMA in copy number (Figures 2C, 2D). The correlation analysis between GSDMA and cancer-related pathways indicated that GSDMA mainly participated in the active regulation of epithelial-mesenchymal transition (EMT), apoptosis, cell cycle, DNA damage response, and hormone estrogen receptor (ER) pathway (Figure 2E). Gene Ontology (GO) functional enrichment analysis indicates GSDMA is associated with the regulation of cell cycle pathway and inhibit apoptosis (Figure 2F, Tables 1 and 2).

Table 1. Biological roles of gasdermin family members.

| Gene name (Gene symbol) | Related signaling pathways | Biological process or Molecular function | Cancer relations | Pore-forming activity | Related diseases |
|-------------------------|---------------------------|-------------------------------------------|----------------|----------------------|-----------------|
| GSDMA | GSDM1 [1, 3]; FKSG9; GSDM1 [3, 4]; ①regulated via TGF-β and LMO1 pathways; ①Active regulation of EMT, apoptosis, cell cycle, DNA damage response, ER pathway; ①Pyroptosis, phosphatidylinositol-4,5-bisphosphate binding; phosphatidylinositol-4-phosphate binding. | | Tumor suppressors | Yes [24] | Asthma [47], Systemic sclerosis [49, 50], Inflammatory Bowel Disease (IBD) [49]. |
| GSDMB | GSDMBL [5]; PP4052; GSDMB-1 [50]; PRO2521 [51]; ①Cleaved by caspase-1, -3, -6, -7, -8, -9 and -9 ③Regulated by TGFβ2 mutation [60]; ①Active regulation of apoptosis and EMT; ①Induces TGF-β1 expression via induction of S-lipoygenase [51]; ①Enzyme-driven HSV thymidine kinase-expressing vector [54]; ①Pyroptosis, phosphatidylinositol-4,5-bisphosphate binding; phosphatidylinositol-4-phosphate binding; phosphatidylinositol-4-phosphate binding. | Oncogene | Yes [24] | Asthma [47], Gastric cancer [11], IBD [49], Glycogen storage disease 1 [55], Gastric cancer [11, 49], Inflammatory Bowel Disease (IBD) [49]. |
| GSDMC | MIZZE [7]; ①Cleaved into two fragments by caspase-8 [33]; ①Active regulation of apoptosis, DNA damage response, and hormone AR pathway; ①Upregulated by TGFβ2 mutation [60]; ①Induced MMP-1 through activation of ERK and JNK pathway [61]; ①TRPV1/calcium/calceinurin/NFATC signaling [61]; ①Pyroptosis, phosphatidylinositol-4,5-bisphosphate binding; phosphatidylinositol-4-phosphate binding; phosphatidylinositol-4-phosphate binding. | Oncogene | Yes [24] | Lumbar spinal stenosis [62] |
| GSDMD | DFS1L; DFNASL [9]; FKSG10; GSDMDC1 [9]; ①Cleaved by caspase-1/4/5/6/11 and neutrophil elastase [31, 52]; ①Cleave as a conduit for the extracellular release of mature IL-1β and IL-18 [63]; ①Involved in the regulation of ERK, STAT3, P38/Akt signaling pathways [52]; ①Promotes the regulation of apoptotic pathways [52]; ①Active regulation of hormone estrogen; ①Regulation of NOD-like receptor signaling pathway and Salmonella infection; ①Inflammammasome or caspase-1-mediated signaling pathways. | Tumor suppressors | Yes [24] | Alzheimer’s disease [65], 2 Inflammation-associated diseases |
| GSDME | DFNAS [8]; ICERE-1 [66, 67]; ①Cleaved by caspase-3 [68]; ①Involved in caspase-3-mediated pyroptosis [69]; ①Involved in the antimassetive activity of ERS1/2 pathway inhibitors [52]; ①Cell cycle; ①MAPK-related pathways [70]; ①Pyroptosis by the activation of caspase-3; ①Sensory perception of sound; ①Sensory perception of mechanical stimul | Tumor suppressors | Yes [24] | Hearing loss [72, 73] |
| PJVK | DFNB59 [6, 10, 74]; ①Cleaved by caspase-1/4/5/6/11 and neutrophil elastase [31, 52]; ①Cleave as a conduit for the extracellular release of mature IL-1β and IL-18 [63]; ①Involved in the regulation of ERK, STAT3, P38/Akt signaling pathways [52]; ①Promotes the regulation of apoptotic pathways [52]; ①Active regulation of hormone estrogen; ①Regulation of NOD-like receptor signaling pathway and Salmonella infection; ①Inflammammasome or caspase-1-mediated signaling pathways. | | | |

2. GSDMA

The GSDM gene is located on human chromosome 17q21.2 [6] (Figure 2A). Humans have only one copy of the gene encoding GSDMA, while mice have three isomers (GSDMA1-3). GSDMA is predominantly expressed in epithelial cells of the skin, differentiated upper gastrointestinal, and lung but is frequently suppressed in primary gastric cancer and gastric cancer cell lines [11, 41]. Moussette et al. have reported that GSDMA expression is up-regulated in the 5-aza-dC, a DNA methyltransferase inhibitor, treatment adenocarcinoma cell line MCF-7 [42]. Saeki et al. found that GSDMA expression is up-regulated through the transforming growth factor-β (TGF-β) and LIM structural domain 1 (LMO1) pathways, thereby promoting apoptosis in gastric epithelial cells [12]. Lin et al. found that Gasdermin A3 N-terminal functional domain modulates mitochondrial homeostasis through mitochondrial targeting [43].

Hu et al. reported that mRNA expression levels of GSDMA were higher in HCC tissues than in normal tissues by UALCAN databases [44]. We also discovered mRNA expression of GSDMA was accordantly higher in HCC tumors (377 TCGA-LIHC) compared with normal tissues (50 TCGA-LIHC paracancerous tissue and 110 GTEX-normal liver tissues) (Figure 2B). Further analysis of the GSDMA revealed the general existence of copy number variation (CNV) mutations. The genetic alteration rate of GSDMA in HCC is about 0.8% and was mainly focused on the amplification in copy number (Figures 2C, 2D). The correlation analysis between six GSDMs and cancer-related pathways indicated that GSDMA mainly participated in the active regulation of epithelial-mesenchymal transition (EMT), apoptosis, cell cycle, DNA damage response, and hormone estrogen receptor (ER) pathway (Figure 2E). Gene Ontology (GO) functional enrichment analysis indicates GSDMA is associated with the regulation of cell cycle pathway and inhibit apoptosis (Figure 2F, Tables 1 and 2). Receiver operating characteristic (ROC) curve
indicates GSDMA had low accuracy in predicting HCC and normal outcomes (area under curve (AUC) = 0.579, confidence interval (CI) = 0.501–0.658, Figure 3A). Besides, GSDMA was positively associated with infiltration of CD8+ T cell, B cell, neutrophil, and dendritic cell [44]. Spearman correlation analysis between expression of GSDMA and infiltration levels of 24 immune cells [45] was performed using single-sample gene-set enrichment analysis (ssGSEA), which is gene set variation analysis (GSVA) package built-in algorithm [46]. We found that GSDMA expression is a significant positive correlation with the infiltration level of activated dendritic cell (aDC), B cells, CD8 T cells, Cytotoxic cells, dendritic cell (DC), Eosinophils, immature dendritic cell (iDC), Macrophages, Mast cells, Neutrophils, NK CD56 bright cells, NK CD56 dim cells, NK cells, plasmacytoid dendritic cell (pDC), T cells, T helper cells, T effector memory cell (Tem), T follicular helper cell (TFH), T helper 1 cells (Th1 cells), and Th2 cells in HCC. In contrast, GSDMA expression is a significant negative correlation with the infiltration level of Th17 cells (P < 0.001, Figure 3H, Table 3).

3. GSDMB

The GSDMB gene is chromosomally mapped at 17q12 [11] (Figure 2A). The N-terminal structural domain of GSDMB (GSDMA-NT) was discovered to trigger pyroptosis [79]. GSDMB can be cleaved through caspase-1, -3, -4, -6, -7, -8, and -9 [31, 52]. GSDMB can be explored in the esophageal, gastrointestinal tract, liver, colon, lung, and lymphocyte epithelium [6, 11, 53]. Previous studies have indicated that GSDMB is highly expressed in some cancer cells, such as gastric cancer, HCC, CRC, and cervical cancer, et al. Therefore, it is recognized as an oncogene [11, 54, 80, 81]. GSDMB upregulation was associated with poor effect and promoted invasion and metastasis in breast cancer cells [50]. Hu et al. found that expression levels of GSDMB were higher in HCC samples than in normal samples [44]. We also discovered the GSDMB expression is accordantly higher in HCC tumor samples compared with normal samples (Figure 2B). Researchers have indicated that GSDMB is located in ampiclons, a region of the genome that is frequently amplified during cancer development [82]. We found the genetic alteration rate of GSDMB in HCC is about 1.4 % and also was mainly focused on the amplification in copy number (Figures 2C, 2D). The correlation analysis between six GSDMs and cancer-related pathways indicated that GSDMB has mainly participated in the active regulation of apoptosis and EMT (Figure 2E). GO functional enrichment analysis indicates GSDMB is participating in the regulation BP of pyroptosis and MF of phosphatidylinositol-4,5-bisphosphate binding, phosphatidylinositol-bisphosphate binding, phosphatidylinositol-4-phosphate binding (Figure 2F, Tables 1 and 2). ROC curve indicates GSDMB had good accuracy in predicting HCC and normal outcomes (AUC = 0.821, CI = 0.764–0.878, Figure 3B). Besides, GSDMB expression is significant positive associated with the infiltration level of NK CD56 bright cells; and negative related to the infiltration level of CD8 T cells, iDC, Macrophages, Mast cells, Neutrophils, NK CD56 dim cells, NK cells, and Tgd (P < 0.05, Figure 3I, Table 3).

4. GSDMC

GSDMC gene is mapped at 8q24 on the human chromosome [6] (Figure 2A). GSDMC was originally found to be highly expressed in metastatic melanoma cells and is known as a melanoma-derived leucine zipper-containing extranuclear factor (MLZE) [7]. Human GSDMC is expressed in epithelial cells of the upper gastrointestinal tract, trachea, and spleen [11]. In addition, GSDMC exhibited cell-growth inhibition

Figure 1. Gadermin family members and cell cleavage. Except for PJVK, the N-terminal structural domains released by GSDMA-E exhibit pore-forming activity on cell membranes and are effectors of pyroptosis. 1) The N-terminal end of GSDMB can be transmitted to mitochondria via the translocase of outer mitochondrial membrane 70 (Tom70) receptor, which then interacts with the mitochondrial partner TNF receptor-associated protein 1 (TRAP1) to contribute to the production of reactive oxygen species (ROS) [31]. 2) Chemotherapeutic agents or targeted therapeutic agents cause permeabilizes mitochondrial membrane that results in cytochrome c release, and ultimately caspase-3 activation augments. In turn, activated caspase-3 cleaves GSDME and induces pyroptosis. 3) Caspase-1 successively promotes IL-1β and IL-18 precursor maturation and cleaves GSDMD. The pore form domain of GSDMD associates with the plasma membrane to shape the GSDMD pore, leading to the release of intracellular contents, including IL-1β and IL-18. Activated caspase-11 (caspase-4/5 in humans) successively cleaves GSDMD and induces pyroptosis [32]. 4) GSDMB can be cleaved through caspase-1, -3, -4, -6, -7, -8, -9, and the fibrinogen-like domain of GSDMC (GSDMC-FL) is released via caspase-8 with TNF (caspase-11/12 in humans) successively cleaves GSDMD and induces pyroptosis [32]. 5) GSDMC may be particularly cleaved via caspase-8 with TNF (caspase-11/12 in humans) successively cleaves GSDMD and induces pyroptosis [32]. 6) PJVK may be involved in large protein transport.
activity in some esophageal squamous cell carcinomas cells and gastric cancer cells, which implies its role as a tumor suppressor [11]. However, GSDMC may have a contrary effect in specific cancers, such as GSDMC was up-regulated in CRC and over-expression of GSDMC facilitated the proliferation and tumorigenesis in CRC cells [60]. These conflicting results suggest that the role of GSDMC in tumor development is ambiguous and needs to be confirmed by further studies. Similar to other GSDMs, GSDMC is also involved in regulating the process of pyroptosis. Hou et al.

Figure 2. Multi-omics analysis of GSDMs in HCC (A) The copy number variation (CNV) alteration site of six GSDMs on 23 human chromosomes. We obtained the CNV frequencies of the six GSDMs in each HCC patient from an online exploration tool- UCSC Xena (http://xena.ucsc.edu/) [77]. The R package “circcos” was used to visualize the location of six GSDMs in human chromosomes (B) Differential expression of six GSDMs in normal and tumor samples of HCC (C, D) CNV variation frequency of six GSDMs in the TCGA-HCC cohort. The CNV was divided into two subtypes, homozygous CNV and heterozygous CNV, which represent the occurrence of CNV on both two chromosomes or only one. Percentage statistics based on subtypes of CNV used GISTIC processed CNV data, and calculation of correlation used mRNA RSEM data and raw CNV data (C) A red dot indicates amplification, and a blue dot indicates the deletion of CNV type (D) Horizontal coordinates represent the genetic alteration type of GSDMs, and the vertical coordinates represent the alteration frequency of CNV in each GSDM. Different rectangular blocks represent different mutation types. Brown, inframe mutation, green, missense mutation; orange, splice mutation; dark blue, truncating mutation; red, amplification; blue, deep deletion; grey, no alterations (E) The cancer-related signaling pathways are regulated by six GSDMs. Red indicates pathway activation; blue indicates pathway inhibition. GSCALite (http://bioinfo.life.hust.edu.cn/web/GSCALite/), a web-based analysis platform for gene-pooled cancer analysis [78], was used to explore the GSDMs involved in the regulation of cancer-associated pathways (activation and inhibition). The pathway we included: Apoptosis pathways, Cell Cycle, DNA Damage Response, EMT, Hormone AR, Hormone ER, PI3K/AKT, RAS/MAPK, RTK, and TSC/mTOR. They are all famous cancer-related pathways. The Gene expression was divided into two groups (High and Low) through the median expression, student T-test was used to define the difference of pathway activity score (PAS) between two groups, p-value was adjusted by FDR, FDR<0.05 is considered as significant. When PAS (Gene A in groupHigh) > PAS (Gene A in groupLow), we consider gene A might have an activating effect on a pathway, otherwise have an inhibiting effect on a pathway [78] (F) Functional annotation analysis for six GSDMs through GO enrichment analysis and KEGG pathway analysis. We use the clusterProfiler package [version 3.14.3] to analyze the data, and the ggplot2 package [version 3.3.3] to visualize the results. The length of the bars in the bar graph from longest to shortest indicates the number of enriched genes from most to least. GO, Gene Ontology; blue indicates biological processes (BP); red presents cellular components (CC); green demonstrated molecular functions (MF), and sky blue presents Kyoto Encyclopedia of Genes and Genomes (KEGG).
we found that GSDMC expression has a significant positive correlation with the infiltration level of aDC, iDC, Macrophages, Mast cells, Neutrophils, NK CD56 bright cells, NK cells, T helper Tem, TFH, Th1 cells, and a negative correlation with the infiltration level of Eosinophils and T helper cells (P < 0.05, Figure 3J, Table 3).

5. GSDMD

GSDMD is the most characteristic member of the GSDM family and has been recognized as an end-effector of pyroptotic [52]. GSDMD gene locates at 8q24.3 in the human chromosome (Figure 2A) and appears to play a role in the regulation of epithelial proliferation, such as skin, esophagus, and stomach epithelium [5, 11]. Among all GSDMs, GSDMD has the most potent inhibitory effect on cell growth and is considered to be a tumor suppressor gene [11]. The GSDMD molecule maintains auto-inhibitory accordance relying mainly on the function of its C-terminal structural domain (GSDMD-CT) [28]. Since the identification of GSDMD, pyroptosis has been reconsidered as GSDM-mediated programmed necrosis [14, 15, 63]. Several studies have recently discovered that pyroptosis can influence tumor proliferation, invasion, metastasis, and anticancer immunity and is regulated by several non-coding RNAs and other molecules [40, 84, 85]. Of course, GSDMD is also involved in regulating the process of cancer development. Wang et al. reported that GSDMD expression is down-regulated in GC cells and tissues compared to normal tissues [86]. Reduced GSDMD expression significantly facilitated GC cell proliferation by activating some signaling pathways, such as ERK, STAT3, PI3K/Akt, et al. [52]. Gao et al. found that down-regulation of GSDMD inhibits tumor proliferation by inhibiting EGF/Akt signaling and endogenous mitochondrial apoptotic pathway and predicts good prognosis in non-small cell lung cancer [64].

Hu et al. found that GSDMD expression was higher in HCC tissues than in normal tissues [44]. We also discovered that the mRNA expression level of GSDMD was higher in HCC tumor samples than in corresponding normal samples (Figure 2B). GSDMD has the highest rate of genetic alterations among GSDMs in HCC, about 11%, and was mainly focused on amplification (Figures 2C, 2D). The correlation analysis between six GSDMs and cancer-related pathways indicated that GSDMC was mainly involved in the active regulation of apoptosis, DNA damage response, and the hormone AR pathway (Figure 2E). GO functional enrichment analysis demonstrates GSDMC is associated with the regulation BP of pyroptosis and MF of phosphatidylinositol-4, 5-bisphosphate binding, phosphatidylinositol-4-phosphate binding (Figure 2F). ROC curve indicates GSDMD had good accuracy in predicting HCC and normal outcomes (AUC = 0.885, CI = 0.846–0.924, Figure 3C). Besides, we found that GSDMD expression has a significant positive correlation with the infiltration level of aDC, iDC, Macrophages, Mast cells, Neutrophils, NK CD56 bright cells, NK cells, T helper Tem, TFH, Th1 cells, and Th2 cells. On the contrary, GSDMD expression is a significant negative correlation with the infiltration level of CD8 T cells and Th17 cells (P < 0.05, Figure 3J, Table 3).

6. GSDME

GSDME, initially identified as deafness autosomal dominant 5 (DFNAS), is positioned at 7p15 on the human chromosome [72, 73] (Figure 2A). GSDME can be explored in the heart, kidney, brain, and placenta [87]. Wang et al. discovered that GSDME expression was different in cancer cells and normal tissues [69]. Since the discovery of GSDME, numerous studies have revealed its underlying role in gastric cancer [86], CRC [89, 90], and breast cancer [91]. Several previous studies have reported GSDME as a tumor suppressor, Kim et al. found that GSDME can significantly inhibit CRC cell colony-forming and growth ability [89]. Rogers et al. discovered that GSDME-deficient melanoma cells grew larger than wild-type melanoma cells [71]. Reversal of low GSDME expression in gastric cancer tissues by decitabine enhances the efficacy of chemotherapeutic agents [68].

Table 2. GO functional enrichment and KEGG pathway analysis of GSDMs.

| Ontology | ID     | Description                        | GeneRatio | BgRatio | P value | p.adjust | Gene ID                                                                 |
|----------|--------|------------------------------------|-----------|---------|---------|----------|-------------------------------------------------------------------------|
| BP       | GO:0070263 | pyroptosis                          | 5,6       | 11,18670 | 1.47e–16 | 8.07e–15 | GSDME, GSDMB, GSDMC, GSDMD, GSDMA                                       |
| BP       | GO:0077605 | sensory perception of sound         | 2,6       | 145,18670 | 8.80e–04 | 0.021   | GSDME, PJVK                                                            |
| BP       | GO:0059554 | sensory perception of mechanical stimulus | 2,6     | 165,18670 | 0.001    | 0.021   | GSDME, PJVK                                                            |
| CC       | GO:0061702 | inflammasome complex                | 1,6       | 14,19717  | 0.004    | 0.051   | GSDMD                                                                 |
| CC       | GO:1904724 | tertiary granule lumen              | 1,6       | 55,19717  | 0.017    | 0.075   | GSDM                                                                 |
| CC       | GO:0035580 | specific granule lumen             | 1,6       | 62,19717  | 0.019    | 0.075   | GSDM                                                                 |
| MF       | GO:0005546 | phosphatidylinositol-4,5-bisphosphate binding | 5,5         | 75,17697 | 1.19e–12 | 1.31e–11 | GSDME, GSDMB, GSDMC, GSDMD, GSDMA                                      |
| MF       | GO:1902936 | phosphatidylinositol bisphosphate binding | 5,5         | 110,17697 | 8.46e–12 | 1.16e–11 | GSDME, GSDMB, GSDMC, GSDMD, GSDMA                                      |

Note: BP, biological processes; CC, cellular components; MF, molecular functions; KEGG, Kyoto Encyclopedia of Genes and Genomes.
found that GSDME inhibits HCC cell proliferation through inducing cell cycle arrest [92]. Chemotherapeutic agents or targeted therapeutic agents usually cause GSDME-mediated pyroptosis, unlike GDSMD-mediated pyroptosis [19]. Zhang et al. reported that multitone induces cell death in HCC cells by GSDME-mediated pyroptosis [93]. Shangguan et al. found that Cannabidiol suppresses HCC cell growth in vivo and in vitro by inducing GSDME-mediated pyroptosis [94]. Curcumin enhanced the expression of the GSDME N-terminus and related proteins.

Figure 3. Prognostic analysis of GSDMs and correlation analysis of immune cell infiltration. ROC curves of GSDMs in HCC. R (version 3.6.3) software is used for statistical analysis and visualization, in which R package “pROC” [version 1.17.0.1] is used to analyze data, and R package “ggplot2” [version 3.3.3] is used to visualize the results. The AUC is between 0.5 and 1. The closer the AUC is to 1, the better the diagnostic effect. AUC has lower accuracy when 0.5–0.7, AUC has certain accuracy when 0.7–0.9, and AUC has higher accuracy when it is above 0.9 (A) GSDMA; (B) GSDMB; (C) GSDMC; (D) GSDMD; (E) GSDME; (F) Survival curves (OS) of GSDME in the high and low expression groups. R package “Survival” [version 3.2–10] is used for statistical analysis of survival data, and R package “survminer” [version 0.4.9] is used to visualize the results (H–M) Immune cell correlation analysis between different GSDMs and 24 immune cells. The data were collected from RNAseq data in level 3 HTSeq-FPKM format of TCGA (https://portal.gdc.cancer.gov/) LIHC (hepatocellular carcinoma) project, which is converted to TPM (transcripts per million reads) format and transformed into log2, and then filtered (excluding control/normal (not all items have control/normal). The markers of 24 kinds of immune cells came from Bindea’s study [45]. We use the built-in algorithm ssGSEA of the “GSVA” package [version 1.34.0] to calculate immune cell infiltration, and then use the Spearman method to analyze the correlation. The results were shown by lollipop charts (H) GSDMA; (I) GSDMB; (J) GSDMC; (K) GSDMD; (L) GSDME; (M) PJVK. We performed the ROC curves and immune cell correlation analysis of the six GSDMs in HCC patients by an online exploration tool- Xiantao Academic (https://www.xiantao.love/).
Table 3. Spearman correlation analysis between GSDMs expression and immune cell infiltration in HCC.

| Immune cells   | Spearman Correlation coefficient/P-value |
|----------------|----------------------------------------|
|                | GSDMA       | GSDMB      | GSDMC      | GSDMD      | GSDME      | PJVK       |
| aDC            | 0.425***    | 0.019      | 0.187***   | 0.177***   | 0.131*     | -0.249***  |
| B cells        | 0.386***    | 0.010      | 0.068      | 0.103*     | 0.100      | -0.266***  |
| CD8 T cells    | 0.173***    | -0.131*    | -0.159**   | -0.042     | -0.103*    | -0.038     |
| Cytotoxic cells| 0.308***    | -0.092     | -0.085     | 0.157**    | -0.119*    | -0.267***  |
| DC             | 0.341***    | -0.085     | 0.078      | 0.060      | 0.000      | -0.278***  |
| Eosinophils    | 0.110*      | -0.086     | -0.047     | -0.202***  | 0.093      | 0.032      |
| iDC            | 0.469***    | -0.155**   | 0.213***   | 0.126*     | 0.156**    | -0.340***  |
| Macrophages    | 0.543***    | -0.102*    | 0.365***   | 0.089      | 0.319***   | -0.288***  |
| Mast cells     | 0.268***    | 0.026***   | 0.146**    | -0.069     | 0.085      | -0.177***  |
| Neutrophils    | 0.228***    | -0.253***  | 0.108*     | -0.012     | 0.010      | -0.273***  |
| NK CDS6 bright cells | 0.188*** | 0.118* | 0.110* | 0.295** | 0.152** | -0.019 |
| NK CDS6 dim cells | 0.218*** | -0.199*** | 0.032 | 0.106* | -0.042 | -0.188*** |
| NK cells       | 0.244***    | -0.235***  | 0.151**    | -0.087     | -0.041     | -0.103*    |
| pDC            | 0.108*      | -0.037     | 0.053      | 0.151      | -0.206***  | -0.148**   |
| T cells        | 0.445***    | -0.024     | 0.054      | 0.177***   | 0.069      | -0.338***  |
| T helper cells | 0.295***    | 0.052      | 0.207***   | -0.181***  | 0.256***   | -0.140**   |
| Tem            | 0.021       | 0.002      | 0.002      | -0.110     | -0.012     | 0.020      |
| Tem            | 0.306***    | -0.068     | 0.150**    | 0.068      | 0.027      | -0.149**   |
| THF            | 0.391***    | -0.065     | 0.172***   | 0.141**    | 0.287***   | -0.166**   |
| Tgd            | 0.091       | -0.160**   | 0.046      | 0.010      | -0.057     | -0.249***  |
| Th1 cells      | 0.477***    | -0.029     | 0.212***   | 0.151**    | 0.136**    | -0.244***  |
| Th17 cells     | -0.206***   | 0.054      | -0.116*    | -0.104     | -0.284***  | -0.040     |
| Th2 cells      | 0.377***    | 0.111      | 0.338***   | 0.159**    | 0.271***   | -0.103*    |
| TReg           | 0.136       | 0.021      | 0.034      | -0.014     | -0.011     | -0.221***  |

Note: aDC, activated dendritic cell; DC, dendritic cell; iDC, immature dendritic cell; pDC, plasmacytoid dendritic cell; Tcm, T central memory cell; Tem, T effector memory cell; Tfh, T follicular helper cell; Tgd, T gamma delta cell. TH, T Helper.

during the pyroptosis, promoted HCC HspG2 cell pyroptosis, and increased intracellular ROS levels [95]. GSDME expression increased the sensitivity of drug-resistant melanoma cells to therapeutic agents via triggering caspase-3-mediated apoptosis [66]. Peng et al. reported that GSDME enhances cisplatin susceptibility for reversing non-small cell lung carcinoma by inducing pyroptosis to induce antitumor immunocyte infiltration [96].

The GSDME gene is expressed in some tumors but is episodically silenced in most tumor cells due to promoter hypermethylation [97]. Hu et al. found that the GSDME expression was higher in HCC samples than in normal samples by UALCAN databases. Besides, high GSDME expression was significantly related to shorter OS in HCC patients [44]. We also discovered that the mRNA expression level of GSDME was higher in HCC tumor tissues than in corresponding normal tissues (Figure 2B). GSDME has the lower rate of genetic alterations among GSDMs in HCC, about 1.1%, and was mainly focused on amplification, Figures 2C, 2D. The correlation analysis between six GSDMs and cancer-related pathways indicated that GSDME was mainly involved in the cell cycle pathway's active regulation and inhibited apoptosis (Figure 2E). GO functional enrichment analysis indicates GSDME is involved in the regulation BP of pyroptosis, sensory perception of sound, sensory perception of the mechanical stimulus, and MF of phosphatidylinositol-4,5-bisphosphate binding, phosphatidylinositol-bisphosphate binding, phosphatidylinositol-4-phosphate binding (Figure 2F, Tables 1 and 2). ROC curve indicates GSDME had moderate accuracy in predicting HCC and normal outcomes (AUC = 0.650, CI = 0.599-0.702, Figure 3E). High GSDME gene expression in HCC has a worse prognosis (HR = 1.84, P = 0.001, Figure 3F).

Besides, we found that GSDME expression is a significant positive correlation with the infiltration level of aDC, iDC, Macrophages, NK CDS6 bright cells, T helper cells, TFH, Th1 cells, and Th2 cells. On the contrary, GSDME expression is significantly negatively associated with the infiltration level of Cytotoxic cells, pDC, and Th17 cells (P < 0.05, Figure SI, Table 3). Based on the given evidence, GSDME could become crucial biomarkers to improve the diagnosis and prognosis of HCC better.

7. PJVK

Pejvakin (PJVK), also known as autosomal recessive deafness type 59 (DFNB59) [8,74], is mapped at 2q31.2-2q31.3 on the human chromosome [72, 74] (Figure 2A). Unlike other GSDMs, the N-terminal structural domains of PJVK cannot be perforated by its C-terminal fragment blocking [14, 24]. The PJVK protein has a shorter C-terminal split, unlike other GSDMs, which share nearly 45% sequence homology, and it is less conserved than other GSDMs [6, 24, 98]. PJVK encoded protein is necessary for the appropriate function of auditory pathway neurons. Defects in this gene are a reason for non-syndromic sensorineural DFNB59 [74]. GSDMA-E has membrane permeation activity and induces pyroptosis, which may be associated with cancer. Research on PJVK has mainly focused on the field of hearing loss [74, 99, 100, 101, 102], while there is little research on the relationship between PJVK and the development of cancer. Hu et al. discovered that the PJVK expression was higher in HCC tissues than in normal tissues in UALCAN databases [44]. We also discovered that PJVK expression was higher in HCC tumor tissues than in corresponding normal tissues (Figure 2B). PJVK has a lower rate of genetic alterations among GSDMs in HCC, about 2%, and was mainly focused on amplification (Figures 2C, 2D). The correlation analysis between six GSDMs and cancer-related pathways indicated that PJVK was mainly involved in the cell cycle pathway's active regulation and inhibited apoptosis (Figure 2E). GO functional enrichment analysis indicates PJVK is involved in the regulation BP of sensory perception of sound and mechanical stimulus (Figure 2F, Tables 1 and 2). ROC curve indicates GSDME had good accuracy in predicting HCC and normal outcomes (AUC = 0.765, CI = 0.704-0.825, Figure 3G). Interestingly, in the immune cell infiltration correlation analysis, PJVK exhibited...
8. Conclusion

GSDMs play modulatory functions in various essential cellular processes, such as cell proliferation, inflammation, and especially pyroptosis. Each member of the GSDM family demonstrates tissue- and stage-specific expression profiles. GSDMs are related to different human diseases, including cancer and inflammation-associated disorders. In addition to GSBM, which promotes the proliferation of some cancer cells, GSDMA, GSDMB, and GSDME all exhibit growth-inhibiting properties of some cancer cells. In addition, the role of GSDMC in cancer cells remains contradictory, with some cancer cells exhibiting oncogenes and some cancer cells exhibiting tumor suppressor genes. The role of PJVK in cancers is still uncertain. All six GSDMs are highly expressed in HCC and have relatively good predictive prognostic power. High GSDME gene expression in HCC has a worse prognosis and can be an essential biomarker to improve the diagnosis and prognosis of HCC better. Besides, the expression of six GSDMs was associated with cancer-related pathways and immune cell infiltration in HCC, but the underlying mechanism is still poorly understood.

Declarations

Author contribution statement
All authors listed have significantly contributed to the development and the writing of this article.

Funding statement
This research did not receive any funding support.

Data availability statement
Data will be made available on request.

Declaration of interest’s statement
The authors declare no conflict of interest.

Additional information
No additional information is available for this paper.

Acknowledgements
Yandong Miao especially thanked Wuxia Quan for her care, patience, and support over the past years

References

[1] N. Saeki, Y. Kuwahara, H. Sasaki, H. Satoh, T. Shiroishi, Gasdermin (Gsdm) localizing to mouse Chromosome 11 is predominantly expressed in upper gastrointestinal tract but significantly suppressed in human gastric cancer cells, Mamm. Genome 11 (9) (2000) 718–724.
[2] H. Sato, T. Koida, H. Manuya, et al., A new mutation Rin3 resembling R(6)ens is mapped close to retinoic acid receptor alpha (Rara) gene on mouse chromosome 11, Mamm. Genome 9 (1) (1998) 20–25.
[3] F. Runkel, A. Marquardt, C. Stegoer, et al., The dominant alopecia phenotypes Bararkin, Bex-denuded, and Reduced coat 2 are caused by mutations in gasdermin 3, Genomics 84 (5) (2004) 824–835.
[4] D.P. Lunn, E. Weed, P.M. Nolan, A. Marquardt, M. Augustin, R.M. Porter, Mutations in gasdermin 3 cause aberrant differentiation of the hair follicle and sebaceous gland, J. Invest. Dermatol. 124 (3) (2005) 615–621.
[5] M. Katoh, M. Katoh, Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenic recombination hotspot around the PIP118B18R-ERBB2 GRB7 amplon, Int J Oncol 24 (3) (2004) 797–793.
[6] M. Tamura, S. Tanaka, T. Fujii, et al., Members of a novel gene family, Gsdm, are expressed exclusively in the epithelium of the skin and gastrointestinal tract in a highly tissue-specific manner, Genomics 89 (3) (2007) 618–625.
[7] K. Watabe, A. Ito, H. Aueda, et al., Structure, expression and chromosomal mapping of MLZE, a novel gene which is preferentially expressed in metastatic melanoma cells, Jpn. J. Cancer Res. 92 (2) (2001) 140–151.
[8] L. Van Laer, E.H. Huizing, M. Verstrekken, et al., Nonsyndromic hearing impairment is associated with a mutation in DPY4N, Nat. Genet. 29 (2) (1998) 194–197.
[9] M. Katoh, M. Katoh, Identification and characterization of human DPY4Ns, mouse Ppyf11a, and rat Dpyf11 genes in silico, Int J Oncol 25 (3) (2004) 765–770.
[10] N. Grillet, M. Schwander, M.S. Hildebrand, et al., Mutations in LOXHD1, an evolutionarily conserved sterol regulatory protein, disrupt hair cell function in mice and cause progressive hearing loss in humans, Am. J. Hum. Genet 83 (5) (2009) 328–337.
[11] N. Saeki, T. Usui, K. Aoyagi, et al., Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium, Genes, Chrom. Cancer 48 (3) (2009) 261–271.
[12] N. Saeki, D.H. Kim, T. Usui, et al., GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGFB-beta-dependent apoptotic signalling, Oncogene 26 (45) (2007) 6488–6498.
[13] J. Shi, W. Gao, F. Shao, Pyroptosis: gasdermin-mediated programmed necrotic cell death, Trends in Biochem. Sci. 42 (4) (2017) 245–254.
[14] J. Shi, Y. Zhao, K. Wang, et al., Cleavage of GSDMB by inflammatory caspases determines pyroptotic cell death, Nature 526 (7575) (2015) 660–665.
[15] N. Kayagaki, I.B. Stowe, B.L. Lee, et al., Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling, Nature 526 (7575) (2015) 666–671.
[16] S. Carl-McGrath, R. Schecken, M. Ebert, et al., Differential expression and localisation of gasdermin-like (GSDML), a novel member of the cancer-associated GSDMDC protein family, in neoplastic and non-neoplastic gastric, hepatic, and colon tissues, Pathology 40 (1) (2008) 13–24.
[17] P. Broz, P. Pelegrin, F. Shao, The gasdermins, a protein family executing cell death and inflammation, Nature Rev. Immunol. 20 (3) (2020) 143–157.
[18] Z. Zhang, Y. Zhang, S. Xia, et al., Gasdermin E suppresses tumour growth by activating anti-tumour immunity, Nature 579 (7799) (2020) 415–420.
[19] Y.Y. Wang, X.L. Liu, R. Zhao, Induction of pyroptosis and its implications in cancer management, Front. Oncol. 9 (2019) 971.
[20] D. Sarri, J. Martínez-Val, Á. Molina-Crespo, L. Sánchez, G. Moreno-Bueno, The multifaceted roles of gasdermins in cancer biology and oncologic therapies, Biochim. Biophys. Acta, Rev. Cancer 1876 (2) (2021), 1868635.
[21] J. Hou, J.M. Hsu, M.C. Hung, Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity, Mol. Cell (2021).
[22] K.W. Chen, B. Demarco, P. Broz, Beyond inflammasomes: emerging function of gasdermin during apoptosis and NETosis, EMBO J. 39 (2) (2020), e103397.
[23] K.W. Chen, M. Monteleone, D. Boucher, et al., Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps, Sci. Immunol. (26) (2018) 3.
[24] J. Ding, K. Wang, W. Liu, et al., Pore-forming activity and structural autoinhibition of the gasdermin family, Nature 535 (7610) (2016) 111–116.
[25] P. Orning, E. Lien, K.A. Fitzgerald, Gasdermins and their role in immunity and inflammation, J. Experim. Med. 216 (11) (2019) 2453–2465.
[26] F. Humphries, L. Shumel-Galia, N. Ketelat-Carnero, et al., Suckication inactivates gasdermin D and blocks pyroptosis, Science (New York, NY) 369 (6511) (2020) 1633–1637.
[27] S. Feng, D. Fox, S.M. Man, Mechanisms of gasdermin family members in inflammation and cell death, J. Mol. Biol. 430 (18 Pt B) (2018) 3068–3080.
[28] S. Kuan, J. Zheng, H. Yang, et al., Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis, Proc. Natl. Acad. Sci. U.S.A 114 (40) (2017) 10642–10647.
[29] Q. Chen, P. Shi, Y. Wang, et al., GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity, J. Mol. Cell Biol. 11 (6) (2019) 496–508.
[30] S.B. Kovacs, F.A. Miao, Gasdermins: effectors of pyroptosis, Trends in Cell Biol. 27 (9) (2017) 673–684.
[31] D. Wu, Y. Chen, Y. Sun, et al., Gasdermin family: a promising therapeutic target for cancers and inflammation-driven diseases, J. Cell Commun. Signal 14 (3) (2020) 293–301.
[32] X. Xia, X. Wang, Z. Cheng, et al., The role of pyroptosis in cancer: pro-cancer or pro-host, Cell Death Dis. 10 (9) (2019) 650.
[33] J. Hou, R. Zhao, W. Xia, et al., PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis, Nat. Cell Biol. 22 (10) (2020) 1264–1275.
[34] H. Sang, J. Ferlay, R.L. Siegel, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin. 71 (3) (2021) 209–249.
[35] J.M. Llovet, R.K. Kelley, A. Villanueva, et al., Hepatocellular carcinoma, Nat. Rev. Biol. 22 (10) (2020) 1264–1275.
[36] C. Estes, H. Razavi, R. Loomba, Z. Younossi, A.J. Sanyal, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology 67 (1) (2018) 123–133.
[38] K. Schulze, S. Imbeaud, E. Letouzé, et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat. Genet. (2021), 505-513.

[39] D. Wu, C. Wei, Y. Li, X. Yang, S. Zhou, Pyroptosis, a new breakthrough in cancer treatment, Front. Oncol. 11 (2021), 698811.

[40] Y. Fang, S. Tian, Y. Fan, et al., Pyroptosis: a new frontier in cancer, Biomed. Pharmacother. 127 (2020), 109965.

[41] K. Hao, Y. Bosé, D.C. Nickle, et al., Lung eQTLs to help reveal the molecular underpinnings of asthma, PLoS Genet. 8 (11) (2012), e1003029.

[42] S. Mousseau, A. Al-Tawajji, H.R. Kohan-Ghadi, et al., Role of DNA methylation in expression regulation of GCP2/GSDMA region in human epithelial cells, PLoS One 12 (2) (2017), e0172707.

[43] P.H. Liu, H.Y. Lin, C.C. Kuo, L.T. Yang, N-terminal functional domain of Gasdermin A3 regulates mitochondrial homeostasis via mitochondrial targeting, J. Biomed. Sci. 22 (1) (2015) 44.

[44] K. Hu, Z. Xu, L. Yao, Y. Yan, L. Zhou, J. Li, Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma, Aging 3 (2021) 13.

[45] G. Bindea, B. Mlecik, M. Tosolini, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity 39 (4) (2013) 782-796.

[46] S. Hanze, R. Castelo, J. Gouin, GSA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinf. 14 (2013) 37.

[47] C. Terao, T. Kawaguchi, P. Diederre, et al., Transnetch meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis, Ann. Rheum. Dis. 76 (6) (2017) 1159-1168.

[48] A. Moreno-Moral, M. Bagnati, S. Koturam, et al., Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk, Ann. Rheum. Dis. 77 (4) (2018) 596-601.

[49] J. Sodevanan, L. Bendayan, A. Almer, Gene expression-genotype Analysis implicates GSDMA, GSDMB, and LRRDC3 as contributors to inflammatory bowel disease susceptibility, BioMed Res. Int. 2015 (2015), B43805.

[50] M. Heruga-Redondo, D. Sarrió, A. Molina-Crespo, et al., Gasdermin B promotes invasion and metastasis in breast cancer cells, PLoS One 9 (1) (2014), e86906.

[51] Y. Yu, C. Zhang, G. Zhou, et al., Gene expression profiling in human fetal liver and identification of tissue- and developmental-stage specific genes through compiled expression profiles and efficient cloning of full-length cDNAs, Genome Res. 11 (8) (2001) 1392-1402.

[52] M. Wang, X. Chen, Y. Zhang, Biological functions of gasdermins in cancer: from molecular mechanisms to therapeutic potential, Front. Cell Dev. Biol. 9 (2021), 697832.

[53] S. Das, M. Miller, A.K. Beppu, et al., GSDMB induces an asthma phenotype characterized by increased airway responsiveness and remodeling without lung inflammation, Proc. National Acad. Sci. USA 113 (46) (2016) 12917-12922.

[54] N. Saeki, R. Komatsu, F. Chikave, K. Yanagihara, H. Sasaki, A GSDMB enhancer-driven HSV thymidine kinase-expressing vector for controlling oculic peritoneal dissemination of gastric cancer cells, BMC Cancer 15 (2015) 439.

[55] T. Ayabe, M. Fukami, T. Ogata, et al., Variants associated with autoimmune Type 1 diabetes in Japanese children: implications for age-specific effects of cis-regulatory haplotypes at 17q12-q21, Diabet. Med. 33 (12) (2016) 1717-1722.

[56] R. Qiu, H. Zhang, H. Zhao, et al., Genetic variants on 17q21 are associated with asphyxial spondylitis susceptibility and severity in a Chinese Han population, Sci. Rep. (2016) 6469.

[57] J. Manjeliukavita, D. Brown, K.A. McGlynn, W. Andenson, C.D. Shriver, K. Zhu, Chemotherapy use and survival among young and middle-aged patients with colon cancer, JAMA surgery 152 (5) (2017) 452-459.

[58] L.H. Kim, H. Chang, J. Oostrik, et al., Involvement of DFNB59 mutations in autosomal dominant progressive sensorineural hearing loss (DFNA5) to chromosome 7p15, Human Mol. Gen. 4 (11) (1995) 2159-2163.

[59] S. Delmaghani, F.J. del Castillo, V. Michel, et al., Mutations in the gene encoding peyjvakin, a newly identified protein of the afferent auditory pathway, cause DFNB59 auditory neuropathy, Nat. Genet. 38 (7) (2006) 770-778.

[60] R. Collin, E. Kalay, J. Oostrik, et al., Alu-derived cis-elements regulate tumorigenesis-dependent gastric expression of GASDERMIN B (GSDMB), Genet. Syst. 85 (1) (2020) 75-83.

[61] A. Liszowska, A. Koszak, M. Liñier, A. Sovóz, E. Sotiri, P.P. Jagodzinski, Analysis of rs6067278 polymorphism in the risk of uterine cervical cancer from a polish population and its impact on gadenmann B expression, Molecular Diágn. Therapy 21 (2) (2017) 199-207.

[62] L. Li, L. Li, L. Bai, Role of GSDMB in pyroptosis and cancer, Cancer Manag. Res. 12 (2020) 3033-3042.

[63] J. Wei, Z. Xu, X. Chen, et al., Overexpression of GSDMC is a prognostic factor for predicting a poor outcome in lung adenocarcinoma, Mol. Med. Rep 21 (1) (2020) 360-370.

[64] R. Tang, J. Xu, B. Zhang, et al., Ferroptosis, necroptosis, and pyroptosis in anticancer immunity, J. Hematol. Oncol. 13 (2020) 110.

[65] C.B. Zhu, J.Y. Fang, The role of pyroptosis in gastrointestinal cancer and immune responses to intestinal microbial infection, Biochim. Biophys. Acta. Rev. Cancer 1872 (1) (2019) 1-10.

[66] J. Shang, F. Wang, P. Chen, et al., Co-Expression network analysis identified COL1A1 is associated with the progression and prognosis in human colon adenocarcinoma, Dig. J. Endor. Gastro. Int. 103 (5) (2018) 1219-1229.

[67] M.S. Webb, A.L. Miller, E.B. Thompson, in CEMs the autosomal deafness gene dfna5 is regulated by glucocorticoids and forskolin, J. Steroid Biochem. Mol. Biol. 107 (1-2) (2007) 15-21.

[68] K. Akino, M. Toyota, H. Suzuki, et al., Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer, Cancer Sci 98 (1) (2007) 88-95.

[69] M.S. Kim, X. Chang, K. Yamashita, et al., Aberrant promoter methylation and tumor suppressor activity of the DFNA5 gene in colorectal carcinoma, Oncogene 27 (25) (2008) 3624-3634.

[70] J. Ibrahim, K. Op de Beeck, E. Fransen, et al., Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer, Cancer Med. 8 (5) (2019) 2133-2145.

[71] E. Cines, M. Beyea, E. Fransen, et al., Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer, Clin. Epigenet. 10 (2018) 51.

[72] C.J. Wang, L. Tang, D.W. Shen, et al., The expression and regulation of DFNA5 in human hepatocellular carcinoma, Mol. Med. Biol. Rep 40 (12) (2013) 6258-6263.

[73] X. Zhang, P. Zhang, L. An, et al., Mitiorone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis, Acta Pharmac. Sinica B 10 (2020) 1397-1413.

[74] F. Shangnan, H. Zhao, N. Ma, et al., A novel mechanism of Cannabinoid in suppressing hepatocellular carcinoma by inducing GSDME dependent pyroptosis, Front. Cell Dev. Biol. 9 (2021), 697632.

[75] W.F. Liang, Y.X. Gong, H.F. Li, et al., Carcimuc activates ROS signaling to promote pyroptosis in hepatocellular carcinoma HepG2 cells, in Vivo 35 (1) (2021) 249-257.

[76] Z. Peng, P. Wang, W. Song, et al., GSDME enhances Gisplatin sensitivity to regress nonsmall cell lung cancer by accelerating pyroptosis to trigger antitumor immunity initiating Signal Transduct. Targeted Ther. 5 (1) (2020) 159.
[97] L. Croes, E. Fransen, M. Hylebos, et al., Determination of the potential tumor-suppressive effects of gsdme in a chemically induced and in a genetically modified intestinal cancer mouse model, Cancers 11 (8) (2019).

[98] B. Demarco, J.P. Graczyk, E. Bjanes, et al., Caspase-8-dependent gasdermin D cleavage promotes antimicrobial defense but confers susceptibility to TNF-induced lethality, Science Adv. 6 (47) (2020).

[99] M. Alimardani, S.M. Hosseini, M.S. Khaniani, et al., Targeted mutation analysis of the SLC26A4, MYO6, PJVK and CDH23 genes in Iranian patients with AR nonsyndromic hearing loss, Fetal and Pediat. Pathol 38 (2) (2019) 93–102.

[100] S. Salime, M. Charif, A. Bousfiha, et al., Homozygous mutations in PJVK and MYO15A genes associated with non-syndromic hearing loss in Moroccan families, Int. J. Pediatr. Otorhinolaryngol. 101 (2017) 25–29.

[101] G. Mujtaha, I. Bukhari, A. Fatima, S. A p Naz, C343S missense mutation in PJVK causes progressive hearing loss, Gene 504 (1) (2012) 98–101.

[102] I. Ebermann, M. Walger, H.P. Scholl, et al., Truncating mutation of the DFNB59 gene causes cochlear hearing impairment and central vestibular dysfunction, Hum Mutat 28 (6) (2007) 571–577.